Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.22.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Total revenue $ 8,486 $ 3,220
Operating expenses:    
Research and development 21,497 21,368
General and administrative 7,620 8,181
Total operating expenses 29,117 29,549
Loss from operations 20,631 26,329
Interest and other income, net 70 52
Interest and other expense, net (1,050) (501)
Net loss 21,611 26,778
Net loss attributable to common shareholders $ 21,611 $ 26,778
Net loss per share attributable to common shareholders:    
Basic and diluted $ 0.38 $ 0.51
Weighted average number of shares used in net loss per share calculations:    
Basic and diluted 56,305,049 52,564,628
Research And Development Revenue, Related Party    
Total revenue $ 0 $ 237
Research And Development Revenue, Other    
Total revenue $ 8,486 $ 2,983